YL413 / MediLink - LARVOL DELTA

YL413: A novel dual-payload anti-HER2 antibody-drug conjugate demonstrating potent preclinical activity (AACR 2026) - "Trastuzumab, topoisomerase I inhibitors, and microtubule inhibitors were expected to demonstrate anti-tumor activity in clinical trials. The dual-payload HER2 ADC exhibited strong anti-tumor activity in vitro and in vivo, indicating potential to overcome Enhertu® resistance. YL413 retains Topo1 inhibitor efficacy, supplemented by a microtubule inhibitor, with possible use in earlier treatment lines."

ADC • Preclinical • Oncology